Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.9152W HIGH $23.57
Volume
404.05 K
Value Traded
6.96 M
Short % Float
24.27%
Days to Cover
4.3
+11.04%Week
-6.28%1 Month
-43.13%3 Month
+58.14%6 Month
-94.93%5 Year
-98.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
257.51 M
EPS (TTM)
3.13
P/E Ratio
2.76
Ent. Value
151.24 M
Total Shares
29.77 M
Float Shares
19.25 M
Insiders
35.34%
Institutions
50.96%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
QTTB Catalyst Timeline
Dated clinical, regulatory and corporate events for Q32 Bio Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Q32 Bio Inc.
191Total events
11Upcoming
45Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Late-BreakerBempikibartPresentation
Late-breaking oral presentation of SIGNAL-AA Part B results at EADV Congress 2026
alopecia areatasource ↗
▲Poster PresentationBempikibartPresentation
Poster presentation of SIGNAL-AA Part B results at EADV Congress 2026
alopecia areatasource ↗
▲Safety Data UpdateBempikibartClinical Data
Safety and tolerability results from SIGNAL-AA Part B presented
alopecia areatasource ↗
▲Full ResultsBempikibartClinical Data
Full 36-week treatment and 16-week off-drug follow-up results from SIGNAL-AA Part B presented
alopecia areatasource ↗
▲Primary Endpoint MetBempikibartClinical Data
Bempikibart met primary endpoint in SIGNAL-AA Part B at Week 36
alopecia areatasource ↗
▲Biomarker DataBempikibartClinical Data
Biomarker and biopsy results from SIGNAL-AA Part B presented
alopecia areatasource ↗
▲PK PD DataBempikibartClinical Data
PK, PD and ADA results from SIGNAL-AA Part B
alopecia areatasource ↗
▲Long Term DataBempikibartClinical Data
Durability data from 16-week off-drug follow-up period of SIGNAL-AA Part B
alopecia areatasource ↗
◆Timing GuidanceBempikibartPresentation
Additional 36-week results and initial 16-week off-drug findings from SIGNAL-AA Part B to be presented at EADV Congress
severe or very severe alopecia areatasource ↗
●Enrollment UpdateBempikibartTrial
Patient enrollment and dosing in SIGNAL-AA Part B OLE ongoing
severe or very severe alopecia areatasource ↗
▼Equity OfferingCorporate
Pricing of $200 million public offering of common stock and pre-funded warrants
▲Topline ReadoutBempikibartClinical Data
Positive 36-week topline results from Part B of SIGNAL-AA
alopecia areatasource ↗
●Oral PresentationBempikibartPresentation
Conference call and webcast featuring KOL Arash Mostaghimi
alopecia areatasource ↗
▼Equity OfferingCorporate
Proposed public offering of $200M common stock and pre-funded warrants
●Trial InitiationBempikibartTrial
Enrollment into open-label extension for Part B ongoing
alopecia areatasource ↗
▲Topline ReadoutBempikibartClinical Data
Q32 Bio announced topline results from SIGNAL-AA Part B
alopecia areatasource ↗
◆Oral PresentationBempikibartPresentation
Presentation of additional 36-week and initial 52-week results at medical conference
severe or very severe alopecia areatasource ↗
◆Topline ReadoutBempikibartClinical Data
SIGNAL-AA Phase 2a Part B Topline Results
alopecia areatasource ↗
◆Topline ReadoutBempikibartClinical Data
Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a trial
alopecia areatasource ↗
▲First Patient DosedBempikibartTrial
First patient dosed in SIGNAL-AA Part B open-label extension
alopecia areatasource ↗
◆Oral PresentationPresentation
Q32 Bio management to participate in fireside chat at 25th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutBempikibartClinical Data
Topline data from Part B of SIGNAL-AA Phase 2a trial
alopecia areatasource ↗
◆Trial CompletionBempikibartTrial
SIGNAL-AA Part A OLE completion expected mid-2026
alopecia areatasource ↗
▲Runway Guidance UpdateCorporate
Cash runway guidance: sufficient into mid-2026 through four Phase 2 milestones
◆Oral PresentationPresentation
Q32 Bio management to participate in fireside chat at Oppenheimer 36th Annual Healthcare Life Sciences Conference
◆Topline ReadoutBempikibartClinical Data
Topline data from SIGNAL-AA Part B expected in first half of 2026
alopecia areatasource ↗
▲Enrollment CompleteBempikibartTrial
Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial
alopecia areatasource ↗
◆Topline ReadoutADX-097Clinical Data
ADX-097 Renal Basket Phase 2 Topline Results
renal basket (IgAN, LN, C3G)source ↗
▲Enrollment CompleteBempikibartTrial
Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial
alopecia areatasource ↗
▲First Patient DosedBempikibartTrial
Dosing of patients in Part A open-label extension (OLE) ongoing
alopecia areatasource ↗
Past FDA Catalysts and PDUFA Decisions
How QTTB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | bempikibart | Phase 2a data presentation | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 37%
Micro Cap(rank 244 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bempikibart Small moleculeNCT05509023 | Atopic Dermatitis | Phase 2 | ACTIVE NOT_RECRUITING | 102 | Dec 1, 2024 | ||||||
| Bempikibart Small moleculeNCT06018428 | Alopecia Areata | Phase 2 | ACTIVE NOT_RECRUITING | 75 | Sep 1, 2026 | ||||||
| Bempikibart Small moleculeCompletedNCT04485481 | Safety Issues | Phase 1 | COMPLETED | 42 | Jan 12, 2022 |
Clinical Trial Results
Readouts, endpoints and source filings for every QTTB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| bempikibart Fast Track | alopecia areata | Phase 2a | 2026-09-30 | Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36Read More | Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Violette Shelia M.Officer (Chief Scientific Officer) | Sell | -917 126,854 held | $8.32 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in QTTB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 1 % (233.3 %) | 52.59 M | 4.13 M | 83.22% ( 1.88 M) |
QTTB Institutional Ownership Trends
QTTB Short Interest
Shares sold short, counted twice a month.
24.27%
Short % of Float
of tradable shares sold short
4.7M
Shares Sold Short
+23.8% vs prior count
4.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.1M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How QTTB ranks across every disease it competes in
Competitive Position is a premium feature
See how QTTB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialQTTB News
QTTB▼ -13.2%on this news
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio presented positive results from Part B of the SIGNAL-AA clinical trial for bempikibart, showing significant efficacy in treating severe alopecia areata. The trial demonstrated meaningful reductions in SALT scores and a favorable safety profile. The company plans to advance bempikibart into a registration-directed program in 2027, aiming to address unmet treatment needs in alopecia areata.
Read more →QTTBQ32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
Q32 Bio announced that results from Part B of the SIGNAL-AA clinical trial of bempikibart will be presented at the EADV Congress. The presentations will include additional 36-week results and initial findings from a 16-week off-drug period. Bempikibart is an anti-IL-7Rα antibody aimed at treating severe alopecia areata. The company emphasizes its commitment to developing innovative therapies for this condition.
Read more →QTTBQ32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
Q32 Bio has appointed Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer. Both bring extensive experience in biotechnology and drug development. Their leadership is expected to advance the company's bempikibart program for alopecia areata, which has shown promising results in clinical trials. The company aims to transition into a registration-directed program in 2027.
Read more →QTTBQ32 Bio to Participate in Upcoming September Investor Conferences
Q32 Bio Inc. announced its participation in three investor conferences in September 2026, including the Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company aims to showcase its innovative therapies for alopecia areata and other autoimmune diseases. Q32 Bio is advancing its candidate bempikibart (ADX-914) in a Phase 2 program, targeting the adaptive immune system.
Read more →QTTBQ32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported positive topline results from the SIGNAL-AA Phase 2a clinical trial for bempikibart, demonstrating significant efficacy in treating severe alopecia areata. The company plans to initiate a registration-directed program in early 2027, following successful financial results, including a $200 million public offering. Ongoing patient enrollment and dosing in the open-label extension of the trial are also highlighted.
Read more →QTTB▼ -15%on this news
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio has announced a public offering of 6,027,399 shares of common stock priced at $18.25 each, along with pre-funded warrants. The offering aims to raise approximately $200 million for working capital, including advancing their treatment bempikibart for alopecia areata. The offering is expected to close on July 16, 2026, pending customary conditions.
Read more →QTTB▼ -13.7%on this news· ran to -30% by day 3shared move
Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio Inc. has announced a proposed public offering of $200 million in common stock and pre-funded warrants. The funds will support clinical development, particularly for bempikibart, a treatment for alopecia areata. The offering is subject to market conditions, and the company has granted underwriters a 30-day option for additional shares.
Read more →QTTB▲ +90.7%on this newsshared move
Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata
Q32 Bio announced positive results from Part B of the SIGNAL-AA clinical trial, showing a 35.3% mean reduction in SALT scores for alopecia areata patients. Notably, 40% of patients achieved a SALT-20 response at Week 36. The treatment demonstrated a favorable safety profile and supports further development towards a registration-directed program in 2027.
Read more →QTTB▲ +90.7%on this newsshared move
Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026
Q32 Bio Inc. will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart in alopecia areata on July 13, 2026. The company will host a conference call to discuss these results, highlighting its focus on innovative therapies for autoimmune diseases. Bempikibart is designed to re-regulate immune function in patients with severe alopecia areata.
Read more →QTTB▲ +81.2%on this news
Q32 Bio Announces $55 Million Private Placement Financing
Q32 Bio Inc. has announced a private placement financing of approximately $55 million, involving the sale of common stock and pre-funded warrants. The placement is expected to close on May 28, 2026, and will support the company's ongoing development of therapies for alopecia areata and other autoimmune diseases. The financing is led by BVF Partners L.P. and includes participation from several institutional investors.
Read more →QTTBQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q32 Bio reported a net loss of $7.6 million for the first quarter of 2026. The company holds $50.8 million in cash and cash equivalents as of March 31, 2026. These funds, combined with other expected proceeds, are projected to support operations through the first half of 2028. The firm also completed a $10.5 million registered direct offering during the period.
Read more →QTTB▼ -7.3%on this news
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
Q32 Bio Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. The company focuses on developing therapies for alopecia areata and other autoimmune diseases. Management will engage in a fireside chat, and a webcast will be available on their website. The company is advancing its Phase 2 program for bempikibart, an innovative treatment for alopecia areata.
Read more →QTTB▲ +17.5%on this news· ran to +35% by day 1
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update -- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand;
Q32 Bio reported its fourth quarter financial results for 2025, highlighting the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial and an increase in its patient size to 33 based on demand. The company also completed a registered direct offering worth $10.5 million and sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics. The upcoming topline results from the clinical trial are expected in mid-2026, and Q32 Bio emphasizes the promising signs for its drug candidate, bempikibart, in treating alopecia areata.
Read more →QTTB▼ -5.4%on this news
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Q32 Bio Inc. (Nasdaq: QTTB) announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference scheduled for February 25, 2026. The company, focused on innovative therapies for autoimmune diseases, will present a fireside chat as part of the event. Q32 Bio is developing bempikibart (ADX-914), an anti-IL-7Rα antibody, to address alopecia areata, a condition affecting approximately 700,000 people in the U.S. The presentation will be accessible through the company's website, allowing for wider audience engagement.
Read more →QTTB▲ +9.7%on this news· ran to +20% by day 3shared move
Q32 Bio Announces $10.5 Million Registered Direct Offering
Q32 Bio has announced a $10.5 million registered direct offering, primarily aimed at advancing its clinical programs for alopecia areata and other autoimmune diseases. The offering involves the sale of shares and pre-funded warrants, led by new and existing institutional investors. Q32 Bio plans to use the net proceeds for working capital and to support future clinical trials of its therapy, bempikibart. The company acknowledges inherent risks in clinical trials that may affect its performance and shareholder value.
Read more →QTTB▲ +74.4%on this news
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million upfront, with potential total payments up to $592 million. This strategic move aims to enhance Q32 Bio's focus on advancing bempikibart for alopecia areata. The company retains its tissue-targeted complement inhibitor platform and continues to evaluate options for its remaining assets.
Read more →QTTB▲ +74.4%on this newsshared move
Q32 Bio Sells Complement Inhibitor ADX-097 -- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments exp
Q32 Bio announced the sale of its complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront and guaranteed milestone payments. This transaction is expected to strengthen Q32's financial position, extending its cash runway into the second half of 2027. The company will continue to focus on advancing bempikibart, its candidate for treating alopecia areata, with topline results from the SIGNAL-AA Phase 2a trial anticipated in mid-2026. Q32 Bio retains rights to its tissue-targeted complement inhibitor platform and will evaluate strategic options for its remaining assets.
Read more →QTTB▼ -9.1%on this news
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q32 Bio completed enrollment in Part B of its SIGNAL-AA Phase 2a trial, expanding the study to 33 patients. The company expects topline data from this trial in mid-2026. Cash and cash equivalents stood at $49.0 million as of September 30, 2025. This balance is expected to fund operations into 2027.
Read more →QTTB▼ -10.8%on this news
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
Q32 Bio has completed enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart, an anti-IL-7Rα antibody targeting alopecia areata. The trial exceeded its initial enrollment target, reflecting high demand. Preliminary data suggest early signs of clinical activity, with topline results expected in mid-2026, potentially leading to pivotal trials.
Read more →QTTBQ32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
Q32 Bio Inc. will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 4th. The company focuses on developing therapies for alopecia areata and other autoimmune diseases. A webcast of the event will be available on their website, with archived replays accessible for 90 days.
Read more →About Q32 Bio Inc.
Headquarters830 WINTER STREET, WALTHAM, MA, 02451
BIOPHARMAWATCH ELITE PLUS
Trade the next QTTB catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime